SLXN
NASDAQSilexion Therapeutics Corp
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
$0.82-0.19 (-18.54%)
News25/Ratings0
News · 26 weeks44-62%
2025-10-262026-04-19
Mix2590d
- SEC Filings11(44%)
- Insider10(40%)
- Other4(16%)
Latest news
25 items- SECSEC Form DEF 14A filed by Silexion Therapeutics CorpDEF 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form PRE 14A filed by Silexion Therapeutics CorpPRE 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- INSIDERSEC Form 4 filed by Shirvan Mitchell4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Leadership Update8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic CancerSignificant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS-driven cancers with significant unmet medical need Company reported strong positive preclinical study results demonstrating significant anti-tumor activity in multiple models and announced successful completion of toxicology studies, and constructive regulatory engagement supporting the Phase 2/3 trial design Silexion expects to initiate human clinical trials in the second quarter of 2026 Grand Cayman, Cayman Islands, March 24, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeu
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateThroughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential During the fourth quarter, Silexion achieved key clinical readiness milestones including completing two-species toxicology studies, written Scientific Advice from Germany's BfArM, and submission of Phase 2/3 clinical trial application to the Ministry of Health in Israel for SIL204 in locally advanced pancreatic cancer The Company remains on track to initiate Phase 2/3 clinical trial in the first half of 2026, with Israel regulatory feedback anticipated
- SECSEC Form 10-K filed by Silexion Therapeutics Corp10-K - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form DEFA14A filed by Silexion Therapeutics CorpDEFA14A - Silexion Therapeutics Corp (0002022416) (Filer)
- PRSilexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General MeetingGrand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. ("Silexion" or the "Company"), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the upcoming Extraordinary General Meeting of Shareholders (the "EGM"), scheduled to be held on March 16, 2026. At the EGM, shareholders will be asked to vote on proposals relating to: Authorized Share Capital Increase Proposal: An increase to the authorized share capital of the Company by 50,000,000 ordinary shares, from US$121,500 divided into 9,000,000 ordinary shares of a par value of US$0.0135 each (which is our current authorized share capital), to US$796,500 divided into 59,
- INSIDERDirector Noy Shlomo was granted 9,091 units of Ordinary Shares (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERDirector Alon Ruth was granted 9,091 units of Ordinary Shares, increasing direct ownership by 800% to 10,228 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERCSO and CDO Shirvan Mitchell was granted 49,726 units of Ordinary Shares, increasing direct ownership by 5,069% to 50,707 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERCFO and Secretary Horenshtein Hadar Mirit was granted 49,726 units of Ordinary Shares, increasing direct ownership by 11,840% to 50,146 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERChairman and CEO Hadar Ilan was granted 64,350 units of Ordinary Shares, increasing direct ownership by 5,740% to 65,471 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERDirector Abramov Dror Yosef was granted 9,091 units of Ordinary Shares, increasing direct ownership by 835% to 10,180 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERDirector Peled Amnon was granted 7,576 units of Ordinary Shares, increasing direct ownership by 1,146% to 8,237 units (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- INSIDERDirector Lushi Avner was granted 9,091 units of Ordinary Shares (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)
- SECSEC Form DEF 14A filed by Silexion Therapeutics CorpDEF 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSEC Form S-8 filed by Silexion Therapeutics CorpS-8 - Silexion Therapeutics Corp (0002022416) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Silexion Therapeutics CorpSCHEDULE 13G/A - Silexion Therapeutics Corp (0002022416) (Subject)
- SECSEC Form PRE 14A filed by Silexion Therapeutics CorpPRE 14A - Silexion Therapeutics Corp (0002022416) (Filer)
- SECSilexion Therapeutics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Silexion Therapeutics Corp (0002022416) (Filer)
- INSIDERDirector Levin Ilan disposed of 5,550 units of Ordinary Shares and was granted 450,000 units of Ordinary Shares (SEC Form 4)4 - Silexion Therapeutics Corp (0002022416) (Issuer)